CUNNINGHAM SEAN LAURENCE
Known title: DirectorCIK: 0001829753
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
Transaction History
| MRVI | ▲ Buy | Grant | 46,293 | $0 | 5/26/2026 | View on chart |
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| MRVI | ▲ Buy | Grant | 89,139 | $193K | 6/16/2025 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| SHC | ▲ Buy | Grant | 20,089 | $0 | 5/24/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 20,645 | $223K | 5/23/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 24,000 | $0 | 7/17/2023 | View on chart |
| SHC | ▲ Buy | Grant | 15,712 | $0 | 5/26/2023 | View on chart |
| SHC | ▲ Buy | Grant | 10,643 | $0 | 5/27/2022 | View on chart |
| MRVI | ▲ Buy | Grant | 4,271 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript
Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.